Fayetteville

Researchers are evaluating the performance of two new blood-based tests designed to help detect cancer in adults aged 45 and older who show symptoms or signs that suggest cancer might be present. These tests focus on multiple cancers, including those in the gastrointestinal system, to improve early diagnosis and guide further medical evaluation. Participants will have up to 40 mL of blood collected for analysis with the investigational diagnostic tests. For those suspected of having cancer, standard diagnostic procedures will be followed to confirm the diagnosis, while participants already diagnosed with cancer must not have started treatment prior to enrollment. The results of the investigational tests will be kept confidential and will not influence clinical care decisions, ensuring unbiased evaluation. During the 18 months following enrollment, researchers will assess the accuracy and performance of these diagnostic tests by comparing their results with clinical diagnoses confirmed through standard care. Participants may undergo routine clinical evaluations, imaging, and pathology reviews as part of their care. The study team will monitor outcomes and maintain blinding to test results to ensure objective assessment throughout the study period.

Researchers are evaluating the Shield blood test as a screening tool for colorectal cancer (CRC) in people aged 45 to 81 who are at average risk for CRC. This study aims to assess how well the Shield test performs during a second round of testing, using colonoscopy as the standard comparison. Colorectal cancer is a common and serious disease, especially in older adults, and early detection through screening can reduce mortality by catching cancer at earlier, more treatable stages. Participants will undergo the Shield blood test as part of their standard care. The study focuses on average-risk individuals who do not have symptoms or high-risk factors for CRC. The performance of the Shield test will be monitored over a period of 33 to 42 months after enrollment to evaluate its effectiveness compared to colonoscopy results. During the study, participants will follow study procedures and standard care assessments. Researchers will measure the performance of the Shield test in detecting colorectal cancer and its precursors during the second testing interval. This includes ongoing monitoring and data collection to understand the test's accuracy and reliability in a real-world setting, with a total follow-up period extending beyond two and a half years.